Selected research
Industry Research
Drugs for Duchenne Muscular Dystrophy (DMD) Industry Research Report 2026
Market perspective
The global Drugs for Duchenne Muscular Dystrophy (DMD) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Drugs for Duchenne Muscular Dystrophy (DMD) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Drugs for Duchenne Muscular Dystrophy (DMD) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Drugs for Duchenne Muscular Dystrophy (DMD) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Drugs for Duchenne Muscular Dystrophy (DMD) include Bristol-Myers Squibb, Italfarmaco, PTC Therapeutics, Santhera Pharmaceuticals, Sarepta Therapeutics, WaVe life Science and Pfizer, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Drugs for Duchenne Muscular Dystrophy (DMD) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Drugs for Duchenne Muscular Dystrophy (DMD).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Drugs for Duchenne Muscular Dystrophy (DMD) Market by Company
Bristol-Myers Squibb
Italfarmaco
PTC Therapeutics
Santhera Pharmaceuticals
Sarepta Therapeutics
WaVe life Science
Pfizer
Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
Eteplirsen
Deflazacort
Ataluren
Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
Home Care
Hospitals
Clinics
Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Duchenne Muscular Dystrophy (DMD) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs for Duchenne Muscular Dystrophy (DMD) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Duchenne Muscular Dystrophy (DMD).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Drugs for Duchenne Muscular Dystrophy (DMD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Eteplirsen
- Deflazacort
- Ataluren
Applications
- Home Care
- Hospitals
- Clinics
Companies covered
- Bristol-Myers Squibb
- Italfarmaco
- PTC Therapeutics
- Santhera Pharmaceuticals
- Sarepta Therapeutics
- WaVe life Science
- Pfizer
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Drugs for Duchenne Muscular Dystrophy (DMD) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Eteplirsen
- 2.2.3 Deflazacort
- 2.2.4 Ataluren
- 2.3 Drugs for Duchenne Muscular Dystrophy (DMD) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Home Care
- 2.3.3 Hospitals
- 2.3.4 Clinics
- 2.4 Assumptions and Limitations
3 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Type
- 3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Type (2021-2026)
- 3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Type (2027-2032)
4 Drugs for Duchenne Muscular Dystrophy (DMD) Breakdown Data by Application
- 4.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Application (2021-2026)
- 4.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Perspective (2021-2032)
- 5.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Growth Trends by Region
- 5.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Historic Market Size by Region (2021-2026)
- 5.2.3 Drugs for Duchenne Muscular Dystrophy (DMD) Forecasted Market Size by Region (2027-2032)
- 5.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Dynamics
- 5.3.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Trends
- 5.3.2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Drivers
- 5.3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
- 5.3.4 Drugs for Duchenne Muscular Dystrophy (DMD) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue
- 6.1.1 Global Top Drugs for Duchenne Muscular Dystrophy (DMD) Players by Revenue (2021-2026)
- 6.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Players (2021-2026)
- 6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Drugs for Duchenne Muscular Dystrophy (DMD) Head Office and Area Served
- 6.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Players, Product Type & Application
- 6.5 Global Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturers Established Date
- 6.6 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
- 7.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
- 7.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
- 8.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
- 8.4 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
- 9.2 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
- 10.2 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
- 10.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (2021-2032)
- 11.2 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bristol-Myers Squibb
- 12.1.1 Bristol-Myers Squibb Company Information
- 12.1.2 Bristol-Myers Squibb Business Overview
- 12.1.3 Bristol-Myers Squibb Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.1.4 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.1.5 Bristol-Myers Squibb Recent Developments
- 12.2 Italfarmaco
- 12.2.1 Italfarmaco Company Information
- 12.2.2 Italfarmaco Business Overview
- 12.2.3 Italfarmaco Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.2.4 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.2.5 Italfarmaco Recent Developments
- 12.3 PTC Therapeutics
- 12.3.1 PTC Therapeutics Company Information
- 12.3.2 PTC Therapeutics Business Overview
- 12.3.3 PTC Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.3.4 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.3.5 PTC Therapeutics Recent Developments
- 12.4 Santhera Pharmaceuticals
- 12.4.1 Santhera Pharmaceuticals Company Information
- 12.4.2 Santhera Pharmaceuticals Business Overview
- 12.4.3 Santhera Pharmaceuticals Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.4.4 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.4.5 Santhera Pharmaceuticals Recent Developments
- 12.5 Sarepta Therapeutics
- 12.5.1 Sarepta Therapeutics Company Information
- 12.5.2 Sarepta Therapeutics Business Overview
- 12.5.3 Sarepta Therapeutics Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.5.4 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.5.5 Sarepta Therapeutics Recent Developments
- 12.6 WaVe life Science
- 12.6.1 WaVe life Science Company Information
- 12.6.2 WaVe life Science Business Overview
- 12.6.3 WaVe life Science Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.6.4 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.6.5 WaVe life Science Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) Business (2021-2026)
- 12.7.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Portfolio
- 12.7.5 Pfizer Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst